Ozempic-Like Drugs Can Help You Lose Weight, But There's a Catch

A fresh analysis indicates that people who discontinue Ozempic-like medications still retain roughly 25% of the weight they lost for as long as 12 months. The unresolved issue is what that remaining loss actually consists of: researchers cannot yet say how much is fat versus lean muscle mass.

That uncertainty points to a poorly examined side-effect of semaglutide, tirzepatide, and related medicines prescribed for type 2 diabetes or body-weight management. Early evidence suggests that 40–60% of the weight lost during treatment may be lean muscle mass, raising questions about what happens to body composition when treatment ends.

GLP-1 drugs, weight regain, and the fat-to-lean mass ratio

It is already well established that many patients regain weight after stopping these medicines. What remains unclear is what the regained kilograms are made of.

“If the regained weight is disproportionately fat, individuals may ultimately be worse off than before in their fat-to-lean mass ratio, which may have adverse consequences for their health,” explains medical researcher Brajan Budini, co-first author of the study led by a team at the University of Cambridge in the UK.

The paper not only reviews the existing evidence on post-cessation weight gain, but is also the first to model how weight changes could unfold for up to 52 weeks after treatment cessation.

Why people stop Ozempic and Wegovy (and what happens next)

Managing weight after treatment matters at population scale: more than one billion people live with obesity worldwide. GLP-1 medicines have shown striking effectiveness, with some individuals achieving 20% or greater reductions in body weight.

These medications imitate the hormone glucagon-like peptide-1 (GLP-1), which helps regulate blood glucose and suppress appetite. However, because of gastrointestinal and other side effects, alongside high costs or prescription hurdles, around half of patients stop GLP-1 drugs within the first year.

“Drugs such as Ozempic and Wegovy act like brakes on our appetite, making us feel full sooner, which means we eat less and therefore lose weight,” says Budini. “When people stop taking them, they are essentially taking their foot off the brake, and this can lead to rapid weight regain.”

What the evidence shows after stopping semaglutide and tirzepatide

To estimate how much weight returns after discontinuation, the researchers reviewed 48 relevant studies, but quickly encountered practical problems:

• many studies monitored outcomes for only a few weeks
• follow-up timing after stopping medication varied widely
• overall, post-GLP-1 weight gain has been “largely underexplored” in published research, the authors note

To strengthen the analysis, the team narrowed the evidence base to studies meeting strict criteria. Eligible trials had to be:

• randomised
• include more than 100 participants
• report at least 3 kg of weight loss
• include at least one follow-up 12 weeks after the medication was stopped

That filtering left six randomised controlled trials (RCTs) covering more than 3,200 people, with follow-up lasting up to 52 weeks after discontinuing weight-loss drugs.

The modelled trajectory: rapid regain, then slowing

Across this (relatively small) meta-analysis, a consistent pattern emerged: patients tended to regain weight quickly at first, with the pace of regain easing over time.

By one year after stopping GLP-1 treatment, participants had regained about 60% of the weight they had lost while on the medication-meaning they kept off roughly 40% of their treatment-related loss at that point.

Using the same data, the researchers then projected what might happen beyond the 52-week window. Their modelling suggests that regain could start to plateau at around 60 weeks, and then taper off once people have regained about 75% of the weight lost during treatment.

Why might weight regain level off?

The reasons are not yet clear. One possibility is that treatment helps some people establish healthier eating routines or triggers physiological changes-such as shifts in hormone levels or altered hypothalamic function-that persist even after the drug is withdrawn.

At the same time, the body-composition question remains central. If a substantial share of treatment-related loss is muscle, it is uncertain whether lean mass rebounds at the same rate as fat mass once medication ends. The authors also note that newer, highly effective drugs such as semaglutide and tirzepatide appear less protective of lean mass-in other words, they can drive larger overall losses regardless of whether that mass comes from fat or muscle.

What clinicians and patients can do after GLP-1 treatment ends

The authors suggest that prescribing approaches which taper doses (rather than stopping abruptly) may help patients preserve at least some of the fat loss achieved on treatment. They also emphasise that clinicians should actively support changes in diet and physical activity, because these behaviours remain essential for long-term health.

“It’s important that people are given advice on improving their diet and exercise, rather than relying solely on the drugs, as this may help them maintain good habits when they stop taking them,” concludes medical researcher and co-first author Steven Luo.

A practical related consideration-rarely captured in routine follow-up-is direct measurement of body composition. Tools such as DEXA scans or other validated methods can help distinguish fat from lean tissue, which matters because muscle is closely linked to strength, function, and metabolic health. Without this information, a stable number on the scales can mask a worsening fat-to-lean mass ratio.

In addition, strategies that prioritise muscle retention may be particularly relevant during and after GLP-1 use, including progressive resistance training, adequate dietary protein, and a gradual return to maintenance energy intake once medication stops-paired with ongoing clinical monitoring, especially for those using these medicines to manage type 2 diabetes.

This research was published in eClinicalMedicine.